Amgen sets $2.25 per share Q4 dividend

THOUSAND OAKS, Calif. - Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company, announced today that its Board of Directors has declared a fourth-quarter dividend of $2.25 per share. This dividend is payable on December 9, 2024, to stockholders of record at the close of business on November 18, 2024.

The company, which has been a pioneer in the biotechnology industry for over four decades, continues to focus on the development and manufacturing of innovative medicines. Amgen's portfolio includes treatments for cancer, heart disease, osteoporosis, inflammatory diseases, and rare diseases. The company has been recognized for its innovation and named among the "World's Most Innovative Companies" by Fast Company in 2024.

Amgen is a component of the Dow Jones Industrial Average and the Nasdaq-100 Index, representing one of the largest and most innovative non-financial companies on the Nasdaq Stock Market by market capitalization.

The press release also contained forward-looking statements regarding Amgen's collaborations, product sales, acquisitions, and financial projections. These statements are subject to risks and uncertainties that could cause actual results to differ materially from projections. Amgen's performance may be influenced by various factors, including market conditions, regulatory changes, and competitive pressures.

The dividend announcement is part of Amgen's commitment to return value to shareholders and reflects confidence in the company's financial strength and future prospects. This information is based on a press release statement from Amgen.

In other recent news, Amgen has reported positive findings from its Phase 3 MINT trial for UPLIZNA (inebilizumab-cdon), a potential treatment for adults with generalized myasthenia gravis (gMG). The trial successfully met its primary endpoint, showing a significant change in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score at Week 26 for patients treated with UPLIZNA compared to those given a placebo. Notably, this is the first Phase 3 placebo-controlled study for a biologic in gMG that included a protocol-specified tapering of corticosteroids.

Secondary endpoints also demonstrated UPLIZNA's efficacy, with meaningful changes from baseline in the Quantitative Myasthenia Gravis (QMG) score for both acetylcholine receptor autoantibody-positive (AChR+) and muscle-specific kinase autoantibody-positive (MuSK+) populations at Week 26. However, changes in QMG score were not statistically significant in the MuSK+ group.

Dr. Jay Bradner, executive vice president at Amgen, underscored UPLIZNA's potential as a bi-annual infusion and its mechanism targeting CD19+ B cells, key drivers of the disease. Following these promising trial results, Amgen intends to seek approval for UPLIZNA in the U.S. and other key markets for the treatment of gMG. These are recent developments regarding the company's pursuit of innovative treatment solutions for severe autoimmune diseases.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.